Celgene has announced immuno-oncology partnerships with Kyn and Kyn just weeks after being bought by Celgene for $74bn. Celgene will pay Kyn $80m and make an investment giving it the option of licensing development programmes, Kyn Therapeutics ’s aryl hydrocarbon receptor antagonist and its Kynase product. “Obsidian’s technology has the potential to unlock the activity of cell therapy in a number of new settings, particularly against solid tumor malignancies, and this is a prime example of the new technologies that we see enabling broader applications for CAR-T and cell therapies for the treatment of cancer,” said Celgene executive vice president for business development and global alliances Robert Hershberg, in a statement. It will also pay Obsidian an undisclosed amount together with an equity investment entitling it to future milestone payments and royalties. The partnerships mean Celgene could gain the rights to cell therapy product candidates containing CD40L to help treat cancer.
Celgene has announced immuno-oncology partnerships with Kyn and Kyn just weeks after being bought by Celgene for $74bn. Celgene will pay Kyn $80m and make an investment giving it the option of licensing development programmes, Kyn Therapeutics ’s aryl hydrocarbon receptor antagonist and its Kynase product. It will also pay Obsidian an undisclosed amount together with an equity investment entitling it to future milestone payments and royalties. The partnerships mean Celgene could gain the rights to cell therapy product candidates containing CD40L to help treat cancer.